Latest Breaking News On - Met all primary - Page 1 : comparemela.com

Risankizumab outperformed ustekinumab in rates of clinical remission at week 24 and rates of endoscopic remission at week 48, meeting both primary endpoints of the phase 3 trial.

Laurent peyrin birouletRoopal thakkarDrug administrationDevelopment in regulatory affairsUniversity hospital of nancyImage analysis group laurent peyrin birouletNews centerInfinity instituteImage analysis groupUniversity hospitalSimple endoscopy scoreRegulatory affairsMet all primarySecondary endpoints versus stelaraHead to studyOnly specific